FDA sets July 23–24 hearing on seven research peptides

A review in Frontiers in Bioinformatics surveys how big data, modeling and AI are advancing computational antimicrobial peptide (AMP) discovery — a methods-focused look at the research.

FDA briefing documents recommend against adding BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon to the 503A compounding list before the July 23–24 PCAC meeting.

Researchers at Kyushu University report a coumarin-tag method in Analytical Chemistry that improves accurate de novo sequencing of short peptides by mass spectrometry.

Third-party analyses report a substantial share of online research peptides miss stated purity, and note that endotoxin can matter even at ~99% purity — reinforcing why COAs are worth reading.

Several procedural deadlines for the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting on peptides fall within the next few weeks. The committee is scheduled to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon, in their free-base and acetate forms — should be eligible for compounding under…

As scrutiny of research-peptide quality grows, one principle keeps surfacing: a Certificate of Analysis (COA) is only meaningful when it is tied to the exact batch in hand and reports more than a single purity figure. A useful COA generally documents several things together: identity confirmation (commonly by mass spectrometry), purity (typically by HPLC), and…